FDA's Revised Strategic Plan Emphasizes Countermeasures, Biosimilars
This article was originally published in The Pink Sheet Daily
Executive Summary
Other aspects of FDA's approach to drugs and biologics remain the same as they were in last September's draft version of the agency's five-year plan.